- Aptinyx is scheduled to meet with the FDA on April 29, 2021, to discuss the development pathway for NYX-783, a novel oral NMDA receptor modulator for post-traumatic stress disorder treatment. - The drug candidate demonstrated clinically meaningful and significant improvement on the primary endpoint of CAPS-5 Arousal and Reactivity Score in a phase IIa study. - With over 8.5 million Americans affected by PTSD and only two FDA-approved treatments available for more than 20 years, NYX-783 represents a potential breakthrough in addressing this significant unmet medical need.

Aug 3, 2025

返回机构列表

Aptinyx Inc.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（8）

Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD

NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)

Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia

Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers

药物批准

资讯

Aptinyx Prepares for FDA Meeting on Novel PTSD Treatment NYX-783